Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2024-12-13 Notice of Dividend Amou…
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure period for an upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the administrative procedure for shareholder rights. Given its nature as a regulatory notification of a corporate event, it fits best under the RNS category.
2024-12-13 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal announcement of a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) by Pharmicell. It details the contract amount, the counterparty (Doosan Electronics BG), the contract period, and payment terms. Since this is a specific regulatory disclosure regarding a material business contract that does not fit into the other specialized categories like M&A or share issues, it falls under the general regulatory filing category.
2024-12-06 Korean
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Pharmicell regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약 체결). It details the contract amount, the counterparty (UCB PHARMA S.A.), and the contract period. Since this is a specific regulatory announcement of a business contract that does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2024-11-29 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Pharmicell regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) with LG Chem. It details the contract amount, duration, and counterparty. Since this is a specific regulatory disclosure of a material business event (contract signing) that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2024-11-25 Korean
[기재정정]분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Pharmicell Co., Ltd. for the period ending September 30, 2024. It contains detailed financial statements (balance sheets, notes to financial statements), management discussion, and business operations information. It is a formal regulatory filing submitted to the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). Since it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2024
2024-11-12 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Pharmicell Co., Ltd. for the period ending September 30, 2024. It contains detailed financial data, business operations, management discussion, and corporate information. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial information for a period shorter than a full fiscal year. 9M 2024
2024-11-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.